South-East Asia (WHO region) vs Saint Kitts and Nevis: New cases tested for RR-/MDR-TB
South-East Asia (WHO region)
91.0%
in 2024
Saint Kitts and Nevis
100.0%
in 2019
South-East Asia (WHO region) rank
1st
Saint Kitts and Nevis rank
1st
New cases tested for RR-/MDR-TB over time
- South-East Asia (WHO region)
- Saint Kitts and Nevis
How they compare
Saint Kitts and Nevis currently reports 100.0% against 91.0% in South-East Asia (WHO region), a difference of 9.0%.
That makes Saint Kitts and Nevis's figure about 1.1 times South-East Asia (WHO region)'s.
The two have swapped places 1 time across 6 shared years of data; in 2010 it was South-East Asia (WHO region) ahead.
South-East Asia (WHO region) ranks 1st and Saint Kitts and Nevis ranks 1st of 11 groups.
Saint Kitts and Nevis has averaged higher in every one of the 1 decades both report.
Frequently asked questions
- Which has higher new cases tested for rr-/mdr-tb, South-East Asia (WHO region) or Saint Kitts and Nevis?
- Saint Kitts and Nevis, at 100.0% against 91.0% in South-East Asia (WHO region) as of 2019.
- What is the difference in new cases tested for rr-/mdr-tb between South-East Asia (WHO region) and Saint Kitts and Nevis?
- 9.0%, with Saint Kitts and Nevis ahead.
- How many years of comparable data are there for South-East Asia (WHO region) and Saint Kitts and Nevis?
- 6 years are reported by both, from 2010 to 2019.
- How do South-East Asia (WHO region) and Saint Kitts and Nevis rank globally for new cases tested for rr-/mdr-tb?
- South-East Asia (WHO region) ranks 1st and Saint Kitts and Nevis ranks 1st of 11 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as New cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.